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Recent advances of biological drugs have broadened the scope of therapeutic targets for a variety of human
diseases. This holds true for dozens of RNA-based therapeutics currently under clinical investigation for
diseases ranging from genetic disorders to HIV infection to various cancers. These emerging drugs, which
include therapeutic ribozymes, aptamers, and small interfering RNAs (siRNAs), demonstrate the unprece-
dented versatility of RNA. However, RNA is inherently unstable, potentially immunogenic, and typically
requires a delivery vehicle for efficient transport to the targeted cells. These issues have hindered the clinical
progress of some RNA-based drugs and have contributed to mixed results in clinical testing. Nevertheless,
promising results from recent clinical trials suggest that these barriers may be overcome with improved
synthetic delivery carriers and chemical modifications of the RNA therapeutics. This review focuses on the
clinical results of siRNA, RNA aptamer, and ribozyme therapeutics and the prospects for future successes.Introduction
Since the milestone discoveries of catalytic RNAs in the early
1980s and RNA interference in the late 1990s, the biological
understanding of RNA has evolved from simply an intermediate
between DNA and protein to a dynamic and versatile molecule
that regulates the functions of genes and cells in all living organ-
isms (Fire et al., 1998; Guerrier-Takada et al., 1983; Kruger et al.,
1982). These and similar breakthroughs have led to the emer-
gence of numerous types of RNA-based therapeutics that
broaden the range of ‘‘drug-able’’ targets beyond the scope of
existing pharmacological drugs (Melnikova, 2007). RNA-based
therapeutics can be classified by the mechanism of activity,
and include inhibitors of mRNA translation (antisense), the
agents of RNA interference (RNAi), catalytically active RNA
molecules (ribozymes), and RNAs that bind proteins and other
molecular ligands (aptamers).
Despite a number of hurdles encountered along the way, more
than 50 RNA or RNA-derived therapeutics have reached clinical
testing. Challenges with the delivery, specificity, stability, and
immune activation of RNA therapeutics have spawned improve-
ments in synthetic and natural nucleic acid carriers and the
development of chemically modified oligonucleotides (Peer
and Lieberman, 2011). In this review, we will discuss many of
these refinements and highlight several promising therapeutics
currently in the clinic.
RNA is unstable in vivo due to the plethora of ribonucleases
in serum and in cells, and chemical modifications can enhance
desired properties without reducing activity. Chemical modifica-
tions to small interfering RNAs (siRNAs), aptamers, ribozymes,
antisense (AS) oligonucleotides (ONs), and miRNAs may
improve the pharmacokinetic (PK), pharmacodynamic (PD)
properties and reduce immunogenicity. Such modifications in
short synthetic ONs include changes in the sugar, base, or back-
bone and may increase target affinity and specificity, decrease
susceptibility to nuclease degradation, improve PK, and improve
RNAi silencing efficiency. Recent advances in the process of60 Chemistry & Biology 19, January 27, 2012 ª2012 Elsevier Ltd All rsynthesizing modified RNA and DNA molecules have increased
the efficiency and reliability of manufacturing while also reducing
production costs (Sanghvi, 2011). While dozens of different
sugar, base, and backbone modifications are available by ON
synthesis, the variety of chemical modifications for RNA-derived
ONs destined for the clinic include phosphorothioate (PS)
backbone modification; 20-O-methyl (20-OMe), 20-fluoro (20-F),
20-O-methoxyethyl (20-MOE) sugar substitutions; 20-O, 40-C-
methylene linked bicyclic ribonucleotides known as a locked
nucleic acid (LNA); and L-RNA (enantiomer of natural RNA)
ONs known as spiegelmers (Figure 1; Shukla et al., 2010).
The PS backbone modification, in which the nonbridging
phosphate oxygen atom is replaced by a sulfur atom, was one
of the earliest ON modifications and remains widely used in
DNA antisense therapeutics, and to a lesser degree, in aptamers
and siRNAs (Shukla et al., 2010). This simple and inexpensive
chemical modification improves resistance to nucleolytic degra-
dation, elicits RNase H-mediated cleavage of the target mRNA
for antisense applications, and increases affinity for plasma
proteins to hinder renal clearance of the ON (Bennett and
Swayze, 2010; Sanghvi, 2011). Chemical substitutions at the
20-hydroxyl group with 20-OMe, 20-F, or 20-MOE groups often
improve the ON potency, stability, and overall PK and PD
properties. Even greater potency and stability improvements
are observed with the LNA modification (Sanghvi, 2011). Collec-
tively, modifications at the 20 position of the sugar ring, including
20-OMe, 20-F, 20-MOE, and LNA, confer the ON to adopt an
RNA-like C30-endo (N-type) sugar pucker, which is the most
energy-favorable conformation of RNA. Thus, such modifica-
tions increase Watson-Crick binding affinity and, due to the
proximity of the 20-substituent and the 30-phosphate, improve
nuclease resistance (Bennett and Swayze, 2010). In contrast
to the aforementioned modifications, spiegelmers do not
contain any chemical substitutions, but rather are enantiomers
of natural RNAs and thus are utilized as nuclease-resistant
aptamers.ights reserved
Figure 1. Common Chemical Modifications of
Therapeutic Nucleic Acid Analogs
The unmodified RNA structure is shown next to backbone
(50-phosphorothioate), LNA, and 20-substitutions (20-O-
methoxy-ethyl, 20-O-methyl, and 20-fluoro).
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Sequence-specific antisense ONs inhibit gene expression by
alteringmRNAsplicing, arrestingmRNA translation, and inducing
degradation of targetedmRNA by RNase H. Like other RNA- and
DNA-derived therapeutics, antisense ONs often include chemi-
cal modifications to the backbone, base, or sugar to enhance
the properties of the drug, such as PS backbones, 20-O-Me,
20-F, 20-MOE, and LNA substitutions. A detailed survey of these
technologies is beyond the scope of this review due to the wide
variety ofRNAandDNA-basedantisense therapeutics.However,
recent reviews have addressed the current status of clinical
antisense drugs (Bennett and Swayze, 2010; Sanghvi, 2011).
Thoughmost current antisense therapeutics target mRNA, one
clinical drug employs antisense technology to inhibit an endoge-
nous microRNA (miRNA). The dysregulation of endogenous
miRNAs has been linked to numerous diseases, including many
types of cancers (Garzon et al., 2010). Emerging therapeutic
strategies to regulate miRNA activity include antisense-miRNA
ONs (antagomirs) and RNA competitive inhibitors or decoys
(miRNA sponges) (Ebert and Sharp, 2010). Santaris Pharma
A/S developed miravirsen (SPC3649), a locked nucleic acid
(LNA)-modified ON that specifically inhibits the endogenous
microRNA-122 (miR-122), a liver specific miRNA required for the
infection of Hepatitis C virus (HCV). Given the high mutation rate
of HCV, miravirsen targets a critical host factor and thus may
provide an elevated barrier for emergence of viral resistance (Lan-
fordet al., 2010). TwocompletedPhase I trials (NCT00688012and
NCT00979927) have indicated that the drug is well tolerated and
safe. Miravirsen has recently advanced into a Phase IIa clinical
study (NCT01200420) to test safety, tolerability, and efficacy for
treatment-naive patients with chronic HCV genotype 1 infection.
Agents of RNA Interference
The cellular process of RNA interference (RNAi) uses small RNAs
to silence gene expression through posttranscriptional geneChemistry & Biology 19, January 2silencing (PTGS) or transcriptional gene
silencing (TGS), though TGS pathway is not
currently explored for clinical purposes (Casta-
notto and Rossi, 2009). PTGS is regulated
by two distinct mechanisms: translational
repression and degradation of mRNAs with
imperfect complementarity, and sequence-
specific cleavage of perfectly complementary
mRNAs. Endogenous microRNAs (miRNAs)
induce translational repression and mRNA
degradation when the guide (antisense) strand
has limited complementarity to the target
mRNA. The sequence-specific cleavage mech-
anism is exploited by exogenous small inter-
fering RNAs (siRNAs) or short hairpin RNAs
(shRNAs) having perfect or near-perfect
Watson-Crick base-pairing with the intendedmRNA target. The production and processing of miRNAs
requires an ensemble of host machinery that is ultimately guided
by one of the two miRNA strands to the target mRNA (Figure 2).
Likewise, siRNAs and shRNAs utilize many of the same endoge-
nous factors, and siRNA/shRNA therapeutics may compete with
the production/function of natural miRNAs.
In general, primary miRNAs (pri-miRNAs) are processed by
a complex containing Drosha and DiGeorge syndrome critical
region gene 8 (DGCR8) and incorporated into the pre-RISC
complex with Dicer and TAR RNA-binding protein (TRBP)
(Figure 2A; Han et al., 2006). Similarly, the Dicer/TRBP complex
directs the processing of shRNA and double-stranded RNA
(dsRNA) molecules into 21–23 nt siRNAs (Figures 2B and 2C;
Bernstein et al., 2001). One strand (guide or passenger) of the
siRNA is loaded into RNA-Induced Silencing Complex (RISC)
and may direct sequence-specific cleavage of mRNA by perfect
or near-perfect Watson-Crick base-pairing (Martinez et al.,
2002). The Argonaute 2 (AGO2) component of RISC contains
an endonuclease activity that cleaves the target mRNA and the
resulting mRNA fragments are destroyed by cellular exonucle-
ases (Rand et al., 2005). While protected inside RISC, the guide
siRNA strand can be repeatedly used to target other comple-
mentary mRNAs. These remarkable properties have prompted
the widespread usage of synthetic siRNA molecules for the
therapeutic knockdown of endogenous and viral mRNA (David-
son and McCray, 2011).
PTGS may be induced by delivering siRNA molecules to
cells in dsRNA form or by shRNAs that are transcribed within
the cell and processed into siRNAs (Figure 2). To mimic the
Dicer cleavage products that are loaded into RISC, many
RNAi applications in mammals commonly deliver synthetic
siRNAs that are 19–23 base pairs (bp) with 2 nt overhangs
at both 30 ends. However, this symmetric design often allows
either strand (guide or passenger) to be selected into RISC.
As an alternative strategy to bias the strand selection of7, 2012 ª2012 Elsevier Ltd All rights reserved 61
Figure 2. Mammalian PTGS Pathway for miRNAs, shRNAs, and siRNAs
(A) miRNAs are transcribed from DNA as primary miRNAs (pri-miRNAs) and processed into 70 nt stem-loop precursor miRNAs (pre-miRNAs) by Drosha and
DGCR8. The pre-miRNAs are transported to the cytoplasm by dsRNA-binding protein exportin 5, where they are processed into 22 nt miRNA duplexes by the
Dicer/TRBP complex. The imperfectly complementary miRNA duplexes associate with an AGO protein and are loaded into RISC, where the passenger strand is
removed and the guide strand remains to target mRNA for silencing. The resulting mature RISC complex may silence gene expression either by inhibiting the
initiation of translation or by transporting the complex to cytoplasmic processing bodies (p-bodies) where the mRNA is deadenylated and destroyed.
(B) Like miRNAs, shRNAs are transcribed from DNA and undergo similar processing. However, the perfect Watson-Crick base-pairing between the guide strand
and the target mRNA triggers AGO2-mediated cleavage of the mRNA target.
(C) In contrast to shRNAs, siRNAs are artificially introduced into the cytoplasm. All steps of siRNA and shRNA are the same after processing by Dicer/TRBP.
62 Chemistry & Biology 19, January 27, 2012 ª2012 Elsevier Ltd All rights reserved
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30 overhang at one end and a blunt end at the other (Kim et al.,
2005). The resulting Dicer substrate (D-siRNA), with a 25 nt
passenger strand and a 27 nt guide strand, directs the prefer-
ential biogenesis of the guide strand, thereby increasing the
potency of the siRNA and decreasing off-target effects (Amarz-
guioui and Rossi, 2008).
In contrast to siRNAs, which transiently knock down gene
expression after each drug treatment, shRNAs that are constitu-
tively expressed from promoters can induce long-term gene
silencing for the duration of their transcription and biogenesis.
Although elevated levels of shRNAs may be desired to achieve
maximum knockdown of the mRNA target, expression from
strong RNA Pol III promoters can saturate the natural miRNA
machinery resulting in severe toxicity (Castanotto et al., 2007;
Grimm et al., 2010). To avoid saturation of the natural RNAi
machinery, multiple shRNAs can be expressed as a multicis-
tronic transcript from a RNA Pol II promoter or combined with
other non-RNAi therapies like ribozymes and RNA decoys (Li
et al., 2005; Zhang and Rossi, 2010).
Over the past decade, interest in siRNA/shRNA technologies
has surpassed many of the antisense strategies due to variety
of reasons, such as ability of siRNAs to elicit potent target-
specific knockdown of any mRNA, ease of siRNA design and
screening against the mRNA target, and achievement of long-
lasting silencing as the siRNA can retain its catalytic activity in
RISC for long periods (Castanotto and Rossi, 2009). Additionally,
reduction of off-target toxicity and increased potency can be
accomplished by designing siRNA as asymmetric Dicer
substrates to bias the loading of the guide strand (Kim et al.,
2005). Finally, unlike some antisense therapies, which act
stoichiometrically on the mRNA target, siRNAs are constantly
recycled after inducing mRNA cleavage. Moreover, with the
expectation that siRNA-directed cleavage of the mRNA target
occurs between nucleotides 10 and 11 relative to the 50 end of
the guide strand, 50-rapid amplification of cDNA ends (50-
RACE) PCR is used to precisely confirm sequence-specific
cleavage by AGO2 (Soutschek et al., 2004), an important con-
sideration in validating that the siRNA is operating through the
RNAi pathway (Alvarez et al., 2009; Davis et al., 2010; Neff
et al., 2011).
Approximately 22 different siRNA/shRNA therapeutics have
reached clinical testing for the treatment of at least 16 diseases
(Table 1; Burnett et al., 2011). Similar to other RNA-based thera-
peutics, the efficacy of siRNA/shRNA drugs relies on maximizing
targeted delivery while minimizing off-target toxicity and degra-
dation. Delivery methods can be categorized as ex vivo, local
or systemic, and systemic methods can be further classified
as active (targeted) or passive (Peer and Lieberman, 2011). The
current state of clinical trials using different siRNA/shRNA
delivery methods are discussed in more detail below.
Local Delivery of siRNAs
Local delivery of siRNA is advantageous for tissues that are
external and/or locally restricted including ocular, epidermal,
pulmonary, colonic, and pancreatic tissue. Additionally, local
delivery may be suitable for noninvasive therapies that require
patient administration, such as eye drops and nasal sprays.
The treatment of vision loss in age-related macular degenera-
tion (AMD) and diabetic macular edema (DME) using intravitrealChemistry & Biol(IVT) injections were some of the first clinical applications for
siRNAs as these drugs can be delivered directly to ocular tissue
to target well-characterized gene targets for these diseases
(Lares et al., 2010). However, despite some initial successes,
many of these approaches ended with disappointing results.
These siRNAs were designed against the VEGF pathway to
inhibit neovascularization leading to retinal edema and damage.
Opko Health Inc. developed Bevasiranib, a 21 mer siRNA con-
taining two deoxythymidine (dT) residues on both 30 ends, that
was designed to knockdown the mRNA of VEGF A. Although
the therapy demonstrated some biological activity in Phase I
and II trials (NCT00722384 and NCT00259753, respectively),
the Phase III trial (NCT00499590) of Bevasiranib for AMD was
terminated as a result of poor efficacy in reducing vision loss
(Dejneka et al., 2008). Despite the completion of a Phase II
trial (NCT00306904) using Bevasiranib in DME, no Phase III
trial has been announced. Similarly, after the completion of
a Phase I/II trial (NCT00363714), the Allergan siRNA AGN-745
against the VEGF receptor was discontinued in the Phase II
trial (NCT00395057) due to an off-target effect (Cho et al.,
2009; Kleinman et al., 2008). Quark Pharmaceuticals and
Pfizer have tested the PF-655 siRNA therapeutic, which
targets proangiogenic factor RTP801, in Phase I and II trials
for AMD (NCT00725686 and NCT00713518, respectively)
and a now-terminated Phase II trial for DME (NCT00701181).
These siRNAs inadvertently activated Toll-like receptors
(TLRs), leading to the suggestion that modifications to the back-
bone chemistry, the terminal nucleotides, and the particular
siRNA sequences may reduce immunostimulatory responses
(Samuel-Abraham and Leonard, 2010).
Quark Pharmaceuticals has developed the siRNA QPI-1007
with proprietary modifications to the siRNA structure and chem-
istry that maintains drug efficacy while reducing off-target
effects. QPI-1007 is specifically designed to down modulate
caspase-2, a key activator in the apoptotic cascade, as a
treatment for optic nerve-related visual loss (NAION) (Guo
et al., 2002). Preclinical studies suggest that QPI-1007 exhibits
neuroprotective effects in animal models of NAION and glau-
coma. A dose-escalated Phase I trial is currently in development
(NCT01064505).
TransDerm, along with the International Pachyonychia Conge-
nita Consortium (IPCC), has designed the first mutation-specific
siRNA to be used for human therapy. The TD101 siRNA is
directed at the mRNA sequence encompassing the dominant
mutation (N171K) in the keratin 6a gene (KRT6A). This mutation
causes pachyonychia congenita, a rare skin disorder character-
ized by painful calluses on weight-bearing areas and hypertro-
phic nails among other epidermal defects. The siRNA therapy
was administered by intralesional injection in a single patient
using a split body control. Since the Phase Ib therapy
(NCT00716014) was well tolerated and efficacious in reducing
the callus, TransDerm is developing less painful alternatives for
delivering the drug (Leachman et al., 2010), such as an ointment
with lipid-based carriers (GeneCreme) and a dissolvable micro-
needle array (Protrusion Array Device).
Sylentis developed an siRNA drug (SYL040012) against the
beta-2 adrenergic receptor (ADRB2) to inhibit the production of
aqueous humor and thereby relieve intraocular hypertension
(Vaishnaw et al., 2010). The eye drop mode of delivery helpsogy 19, January 27, 2012 ª2012 Elsevier Ltd All rights reserved 63
Table 1. Anti-miRNA and siRNA/shRNA Therapeutics in Clinical Trials
Company Drug Delivery Route Target Vehicle Disease Phase Status
Santaris SPC3649 (LNA) SC miR-122 Naked LNA HCV IIa Ongoing
Opko Health Bevasiranib IVT VEGF Naked siRNA AMD/DME III Terminated
Allergan/ Sirna AGN-745 IVT VEGF-R1 Naked siRNA AMD II Terminated
Quark/Pfizer PF-655 IVT RTP801 Naked siRNA AMD/DME II Completed
Quark Pharma QPI- 1007 IVT Caspase 2 Naked siRNA NAION I Ongoing
TransDerm/
IPCC
TD101 Intralesional
injection
KRT6A(N171K) Naked siRNA Pachyonychia
Congenita
Ib Completed
Sylentis SYL040012 Ophthalmic
drops
ADRB2 Naked siRNA Intraocular Pressure II Ongoing
Sylentis SYL1001 Ophthalmic
drops
TRPV1 Naked siRNA Dry eye syndrome I Ongoing
ZaBeCor Excellair Inhalation Syk kinase unknown Asthma II Ongoing
Alnylam/ Cubist ALN-RSV01 Nebulization
or intransal
RSV
Nucleocapsid
Naked siRNA RSV IIb Ongoing
Marina Biotech CEQ508 Oral Beta catenin tkRNAi in E. Coli FAP/ colon cancer I Ongoing
Silenseed Ltd siG12D LODER EUS biopsy
needle
KRASG12D LODER polymer PDAC I Ongoing
Tekmira TKM-ApoB IV Apo B SNALP Hypercholesterolemia I Terminated
Tekmira TKM-PLK1 IV PLK1 SNALP Solid tumors I Ongoing
Alnylam/ Tekmira ALN-VSP02 IV KSP and VEGF SNALP Solid tumors I Completed
Alnylam ALN-TTR01 IV TTR SNALP TTR-mediated
amyloidosis (ATTR)
I Ongoing
University
Duisburg
Bcr-Abl siRNA IV Bcr-Abl Anionic liposome CML I Completed
Silence
Therapeutics
Atu027 IV PKN3 siRNA-lipoplex Advanced solid
cancer
I Ongoing
Quark Pharma I5NP IV P53 Naked siRNA AKI and DGF II Ongoing
Calando
Pharma
CALAA-01 IV RRM2 Cyclodextrin
nanoparticle,
TF, and PEG
Solid tumors I Ongoing
Gradalis Inc. FANG vaccine Ex vivo IV Furin and
GM-CSF
Electroporation Solid tumors II Ongoing
Duke University iPsiRNA Ex vivo
intradermal
injection
LMP2, LMP7,
MECL1
Transfection Metastatic melanoma I Ongoing
City of Hope/
Benitec
Tat/Rev shRNA Ex vivo
transplant
HIV Tat
and Rev
Lentivirus HIV 0 Ongoing
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initial Phase I trial (NCT00990743) evaluated the safety of
SYL040012 in patients with ocular hypertension and glaucoma,
while a scheduled Phase I/II study (NCT01227291) will continue
to evaluate the tolerance and efficacy of this drug. In September
2011, Sylentis announced a Phase I trial (NCT01438281) for their
second siRNA drug (SYL1001) for the treatment of ocular pain
associated with ‘‘dry eye’’ syndrome. SYL1001 triggers the
knockdown of transient receptor potential cation channel
subfamily V member 1 (TRPV1), also known as the capsaicin
receptor, on the ocular surface, which alleviates ocular surface
irritation, inflammation, and pain in animal models.
ZaBeCor Pharmaceuticals reported improvements in asth-
matic symptoms for patients treated with Excellair in a Phase I
study (Burnett et al., 2011). This siRNA drug inhibits spleen tyro-
sine kinase (Syk), which is involved in activating proinflammatory64 Chemistry & Biology 19, January 27, 2012 ª2012 Elsevier Ltd All rtranscription factors. These benefits have helped usher Excellair
into a Phase II trial.
Alnylam has developed a siRNA therapeutic (ALN-RSV01)
against the respiratory syncytial virus (RSV) nucleocapsid (N)
protein for prophylaxis against RSV infections in healthy patients
(NCT00496821) and for treating RSV infections in lung transplant
patients (NCT00658086 and NCT01065935). The drug is
composed of a double-stranded RNA duplex with 19 base pairs
of complementarity and 2 nt dT overhangs at both 30 ends
(Alvarez et al., 2009). Nasal spray and electronic nebulizer aid
the delivery of the therapeutics to healthy or lung transplant
patients, respectively. The antiviral effect of ALN-RSV01 was
demonstrated by a reduced infection rate in healthy patients
and by alleviating the daily symptoms in transplant patients
(DeVincenzo et al., 2010; Zamora et al., 2011). Although the
clinical trials have not yet shown direct evidence for a humanights reserved
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animal studies (Alvarez et al., 2009).
Marina Biotech has launched a Phase I trial of the first orally
administered shRNA drug for treating familial adenomatous
polyposis (FAP), a rare hereditary disease that often leads to
colon cancer. The CEQ508 shRNA therapy downregulates
b-catenin to slow the polyp growth in intestinal cells (Xiang
et al., 2009). The drug is encapsulated by the company’s
TransKingdom RNA interference (tkRNAi) technology, which
utilizes nonpathogenic Escherichia coli to produce and deliver
the shRNAs to target cells (Nguyen and Fruehauf, 2009). The
bacterial vector is coated with Invasin protein from Yersinia
pseudotuberculosis to facilitate the entry of the bacterial carrier
into intestinal cells expressing the b-1 integrin receptor. Finally,
the vector encodes lysteriolysin O pore forming protein (from
Listeria monocytogenes) to permit the shRNA to escape the
bacterial vehicle and enter the cytoplasm.
Silenseed Ltd is launching a Phase 0/I trial (NCT01188785) to
evaluate an siRNA drug (siG12D) that targets somatic mutations
in the KRAS oncogene (KRASG12D) for pancreatic ductal
adenocarcinoma (PDAC). An endoscopic ultrasound (EUS)
needle is used to inject the siRNA drug directly into the tumor.
The siRNA is encapsulated in the Local Drug EluteR (LODER)
biodegradable polymer, which enables slow release of the siRNA
therapeutic over an 8 week period (Burnett et al., 2011).
Systemic Delivery of siRNAs
Upon intravenous (IV) injection, unmodified siRNAs tend to
accumulate in the kidneys, whereas siRNAs encapsulated in
liposomes and nanoparticles often become trapped in the liver.
Thus, siRNA therapeutics designed for these tissues can be
delivered by nontargeted (passive) systemic delivery, in which
uptake of the therapeutics relies on the filtering organs of the
reticuloendothelial system (Peer and Lieberman, 2011). For
applications that require targeted systemic delivery, synthetic
carriers may be decorated with cell-specific ligands or aptamers
that allow receptor-mediated uptake (Bartlett et al., 2007), and
biodegradable nanoparticle carriers allow for slow drug release
once inside the cell (Li et al., 2010).
Tekmira Pharmaceuticals has developed two distinct siRNA
drugs that are encapsulated in the stable nucleic acid lipid
particle (SNALP). SNALP is a first generation lipid nanoparticle
developed by Tekmira that is designed to deliver the siRNA to
the targeted tissue by IV injection. The first drug (TKM-ApoB or
PRO-040201) is an siRNA that targets the mRNA of ApoB and
is designed to indirectly reduce the uptake of cholesterol in
cells. A total of 17 patients received TKM-ApoB and one of the
two that received the highest dosage of the drug exhibited flu-
like symptoms that were consistent with siRNA induced immune
stimulation (Burnett et al., 2011). Although the drug did not show
evidence of toxicity in the liver, the Phase I clinical study
(NCT00927459) was terminated because patients exhibited
only transient reductions in cholesterol levels (Watts and Corey,
2010). Nonetheless, the company is working on improvements
to the nanoparticle carriers and siRNA design. The second
drug known as TKM-PLK1, which targets polo-like kinase 1
(PLK1), will be tested in two Phase I trials (NCT01262235 and
NCT01437007) for patients with advanced solid tumors that
are resistant to current therapies since downmodulation of
PLK1 levels prevents cell cycle progression into mitosis andChemistry & Biolinduces apoptosis in tumor cells (Reagan-Shaw and Ahmad,
2005).
Alnylam Pharmaceuticals has partnered with Tekmira for the
use of SNALP carriers to package siRNA therapies for two
diseases, liver cancer and transthyretin (TTR)-mediated
amyloidosis (ATTR). To treat hepatocellular carcinoma, Alnylam
generated a therapeutic (ALN-VSP02) with two distinct siRNAs
against vascular endothelial growth factor (VEGF) and kinesin
spindle protein (KSP). The therapy was generally well tolerated
in a Phase I trial (NCT00882180), and an anti-VEGF effect was
observed in most patients and confirmed (Vaishnaw et al.,
2011). Long-term follow up of patients treated with ALN-VSP02
continues in a second Phase I trial (NCT01158079). Additionally,
Alnylam has initiated Phase I study (NCT01148953) to determine
the safety and tolerability of siRNA treatment for ATTR, ALN-
TTR01. The ALN-TTR01 siRNA targets the ttr mRNA to reduce
the accumulation of amyloid deposits in surrounding tissues
(Vaishnaw et al., 2010). Since TTR is mainly expressed in the
liver, Alnylam has teamed with Tekmira to design SNALP carriers
with high affinity for hepatocytes. In November 2011, Alnylam
announced that ATTR patients receiving ALN-TTR01 exhibited
a statistically significant reduction in serum TTR protein levels
that was dose dependent and durable after a single dose.
Taking a similar approach to the Tekmira-designed cationic
SNALP carriers, multiple clinical trials utilize other design strate-
gies for encapsulating the siRNA therapeutics. A Phase I trial
sponsored by the University of Duisburg-Essen (Germany) incor-
porated an siRNA drug against bcr-abl with anionic liposomes.
BCR-ABL is a fusion oncogene uniquely expressed in chronic
myeloid leukemia (CML) resulting from a chromosomal defect.
Despite transient knockdown of the bcr-abl fusion, the inhibition
of the oncogene mRNA was not maintained in patients
(Koldehoff et al., 2007). Silence Therapeutics is conducting
a Phase I trial (NCT00938574) for the treatment of advanced
solid cancers. The Atu027 siRNA is designed to inhibit protein
kinase N3 (PKN3), a downstream target of the phosphoinositide
3-kinase (PI3K) signaling pathway that mediates metastasis of
cancer cells (Santel et al., 2010). The Atu027 therapeutic is
formulated as an siRNA-lipoplex, a complex with negatively
charged nucleic acids and cationic lipids, known as AtuPLEX.
Quark Pharmaceuticals has opted to deliver uncoated siRNA
therapeutics to the kidney for preventing acute kidney injury
(AKI) and delayed graft function (DGF). The natural pathway of
excretion by the kidneys allows internalization of the siRNAs
making this tissue a tractable target for siRNA therapies. A Phase
I trial indicated that the siRNA I5NP (or QPI-1002) temporarily
suppresses the proapoptotic p53 protein as prophylaxis for
AKI postcardiovascular surgeries (NCT00554359). This strategy
is currently in a Phase I/II trial for DGF after kidney transplants
(NCT00802347).
Calando Pharmaceuticals tested the first receptor-mediated
delivery of siRNA nanoparticles as treatment for relapsed/refrac-
tory cancers. In this Phase I trial (NCT00689065), the siRNA is
complexed in cyclodextrin nanoparticles that are coated with
polyethylene glycol (PEG) for stability and the human transferrin
(TF) protein for receptor mediated uptake via the transferrin
receptor, which is often highly expressed in tumor cells. The
siRNACALAA-01 is directed against theM2 subunit of ribonucle-
otide reductase (RRM2), which is essential in providing theogy 19, January 27, 2012 ª2012 Elsevier Ltd All rights reserved 65
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this landmark study also demonstrated first evidence for RNAi
mechanism in humans as the investigators verified the occur-
rence of siRNA-induced cleavage of the target RRM2 mRNA
(Davis et al., 2010).
Ex Vivo Delivery of siRNA/shRNA
Delivery of siRNA/shRNA via bacterial or viral carriers is often
performed ex vivo, as the targeted cells are collected, modified,
and reinfused back into the patient. This delivery method is often
preferred when simultaneous delivery and expression of multiple
therapeutic genes (mRNAs, ribozymes, aptamers, etc.) are
required and/or when a specific cell type (generally leukocytic
lineages) is targeted for therapeutic gene applications.
Two autologous immune cell therapies for cancer combine an
siRNA/shRNA therapeutic with the expression of a recombinant
gene or codelivery of therapeutic mRNA. Gradalis Inc. is treating
advanced solid cancers, including stage IIIc ovarian cancer, in
Phase I (NCT01061840) and Phase II trials (NCT01309230) by
expressing recombinant granulocyte-macrophage colony stim-
ulating factor (GM-CSF) and a bifunctional shRNA against Furin
(bi-shRNAfurin) in the FANG Vaccine (Maples et al., 2010). Both
stem loops in the bi-shRNAfurin target the furin mRNA, but one
contains a perfectly complementary guide strand that induces
mRNA cleavage whereas the other has a guide strand that is
mismatched to the target 30 UTR and therefore functions as
an miRNA. Downregulation of Furin indirectly reduces the trans-
forming growth factor (TGF)-b1 and TGF-b2 isoforms that
contribute to diminished T cell responsiveness in tumor cells.
GM-CSF overexpression induces differentiation of dendritic
cells (DCs) antigen presentation. Therefore, the combined down-
regulation of TGF-b isoforms and overexpression of GM-CSF is
designed to mobilize the patient’s immune cells to eradicate
malignant cells.
A similar Phase I study (NCT00672542) conducted by Duke
University is administering the siRNA/mRNA therapy for meta-
static melanoma. Autologous DCs harvested from patients are
transfected with siRNAs against immunoproteasome subunits
LMP2, LMP7, and MECL1 (iPsiRNA) and subsequently trans-
fected with melanoma antigens MART, MAGE-3, gp100, and
tyrosinase (Dannull et al., 2007). The downregulation of immuno-
proteasomes is believed to enhance presentation of melanoma
antigens by DCs. By boosting proteasome-mediated antigen
presentation in autologous DCs, this strategy enhances the
immune response toward melanoma cells.
The City of Hope, in partnership with Benitec, Inc., has con-
ducted an all RNA based gene therapy human pilot feasibility
(Phase 0) study for patients with AIDS-related non-Hodgkin’s
lymphoma (NHL) (DiGiusto et al., 2010). The four patient cohort
consisted of patients requiring transplantation of autologous
CD34+ hematopoietic progenitor cells (HPCs) for the treatment
of NHL. However, to protect the transplanted progenitor cells,
and particularly the eventual subset of differentiated CD4+
T cells, from HIV infection, a fraction of the cells were transduced
ex vivo with a replication incompetent lentiviral vector that
encoded three anti-HIV small RNAs (pHIV7-shI-TAR-CCR5RZ).
The three small RNAs are each expressed from separate RNA
polymerase III promoters and are designed to inhibit infection
and/or replication of HIV-1 by a distinct mechanism: (1) an
anti-CCR5 ribozyme intended to block viral entry, (2) an shRNA66 Chemistry & Biology 19, January 27, 2012 ª2012 Elsevier Ltd All rdesigned to destroy viral mRNA, and (3) an RNA hairpin known
as the transactivating region (TAR) decoy that antagonizes viral
transactivation (Li et al., 2005). The shRNA component is
designed to induce RISC-mediated cleavage of viral mRNA at
a site with overlapping, frame-shifted reading frames of Tat
and Rev, which mediate transactivation of viral gene expression
and nuclear export of viral mRNA transcripts, respectively. The
therapy was well tolerated and genetic marking of the siRNA
was detected in primary blood mononuclear cells (PBMCs)
and/or primary blood granulocytic cells (PBGCs) of all patients
up to 6 months after treatment, including at least 24 months in
one patient (DiGiusto et al., 2010). A second clinical study with
the same AIDS-related NHL cohort is scheduled to begin in early
2012 (Burnett et al., 2011).
Ligand RNAs: Aptamers and Decoys
Aptamers are single-stranded nucleic acids that bind to molec-
ular targets with high affinity and specificity due to their stable-
three dimensional shapes (Bouchard et al., 2010). Many
aptamers exist as hairpin-like monomers that bind targets via
unpaired nucleotides, but some aptamers function as duplexes
(Huang et al., 2003), triplexes (Sussman and Wilson, 2000), or
quadruplexes (Mashima et al., 2009; Phan et al., 2011). RNA
and DNA aptamers are typically identified for a particular func-
tion through multiple rounds of in vitro or cell-based selection
in a process known as systematic evolution of ligands by expo-
nential enrichment (SELEX) (Ellington and Szostak, 1990; Tuerk
and Gold, 1990). Using SELEX, aptamers of 20–100 nucleotides
(nt) can be selected from libraries (up to 1015 unique
sequences) to bind with high affinity to a wide array of protein
families to modulate the protein function similar to antibodies
(Keefe et al., 2010). Like other RNA therapeutics, RNA aptamers
are often modified during chemical synthesis to increase their
resistance to nucleases and improve pharmacological proper-
ties. These modifications include 20-F, 20-OMe, and LNA sugar
substitutions or the spiegelmer form of the aptamer. Additionally,
aptamers may be conjugated with cholesterol or polyethylene
glycol (PEG) to reduce renal filtration (Keefe et al., 2010).
While the affinity and specificity of RNA aptamers for their
target ligands rival the properties of antibodies, aptamers offer
several advantages over their protein counterparts. Aptamers
are evolved and identified in vitro using SELEX, and can be
reproducibly and economically synthesized in large scale for
clinical applications. Using chemical substitutions and other
modifications (including L-RNA), aptamers elicit minimal immu-
nogenicity relative to antibodies. The small size of aptamers
allows for improved transport and tissue penetration compared
to antibodies. Finally, aptamers are amenable to applications
that require engineering, such as the conjugation of aptamers
to ribozymes (riboswitches) and aptamer-siRNA chimeras.
There are at least 6 RNA-based aptamers or decoys that
have been clinically tested (Table 2), including a VEGF-specific
modified RNA aptamer (Macugen by Pfizer/Eyetech) that is
now an FDA approved drug for the treatment of AMD (Keefe
et al., 2010; Sanghvi, 2011; Thiel and Giangrande, 2009). In
addition to their antibody-like abilities to inhibit or activate the
functions of protein targets, aptamers also offer novel functions
as therapeutic and diagnostic agents. By utilizing Watson-Crick
pairing of nucleic acids, RNA aptamers can be engineered
to undergo conformational changes in the presence and/orights reserved
Table 2. Aptamers and Decoys in Clinical Trials
Company Drug Route Target Modification(s) Disease Phase Status
Eyetech /
Pfizer
Pegaptanib
sodium
(Macugen)
IVT VEGF 20-OMe purine/20-F pyrimidine
with two 20-ribo purines
conjugated to 40 kDa PEG,
30 inverted dT
AMD FDA
approved
Approved
Archemix
Corp.
ARC19499
(BAX499)
IV and SC Tissue factor
pathway
inhibitor (TFPI)
Unknown Hemophilia II Not yet
recruiting
Regado
Biosciences
REG1
(RB006 &
RB007)
IV Factor IXa 20-Ribo purine/20-F pyrimidine
(RB006); PEG and 20-Ome
antidote (RB007)
ACS II Completed
Ophthotech ARC1905 IVT Complement
component
5 (C5)
20-Ribo purine/20-F pyrimidine
conjugated to 40 kDa PEG,
30 inverted dT
AMD I Ongoing
City of Hope /
Benitec
TAR decoy Ex vivo
transplant
HIV Tat protein U6 snoRNA domain HIV 0 Ongoing
Childrens
Hospital
Los Angeles
RRE decoy Ex vivo
transplant
HIV Rev protein Expressed by
HIV promoter
HIV 0 Ongoing
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Reviewabsence of other effector RNAs both in vitro and in vivo. Such
a strategy has been tested in two Phase II trials (NCT00932100
and NCT00113997) with the REG1 (by Regado Biosciences)
dual-aptamer therapy for acute coronary syndrome (ACS). Using
this therapy, the first aptamer RNA aptamer (RB006 or pegniva-
cogin) is administered to bind coagulation factor IXa, but after
the subsequent injection of the second ‘‘antidote’’ aptamer
(RB007 or anivamersen), RB006 binds to RB007 thereby
releasing it from its factor IXa target (Cohen et al., 2010). Also,
aptamers can be combined with other types of therapeutic
agents to serve as a delivery vehicle for siRNAs (McNamara
et al., 2006; Neff et al., 2011; Pastor et al., 2010), enzymes
(Chen et al., 2008), and anticancer drugs (Hicke et al., 2006;
Hwang et al., 2010). Finally, although no clinical applications
have yet been demonstrated, RNA aptamers can be engineered
to form self-organizing RNA scaffolds (Delebecque et al., 2011),
combined with ribozymes to create ‘‘riboswitches’’ (Serganov
and Patel, 2007), or conjugated to miRNAs to create ligand-
responsive miRNAs (Beisel et al., 2011). While many of these
therapeutic aptamers consist of RNA-based molecules with
20-OMe and/or 20-F substitutions and PEG conjugation,
numerous examples of DNA and spiegelmer aptamers are also
in the clinic (Keefe et al., 2010).
While the SELEX technique enables the discovery of novel
RNA and DNA aptamers, mimics of protein-binding RNAs can
be used as therapeutic decoys. Like RNA aptamers, RNA
decoys bind target proteins due to their three-dimensional struc-
ture. Two examples of clinically tested RNA decoys have both
been used to inhibit HIV-1 replication (Haasnoot and Berkhout,
2009). The Rev response element (RRE) decoy is composed of
the 41 nt RRE portion of HIV-1 transcripts, which is a hairpin-
like structure that binds to the viral Rev protein (Kohn et al.,
1999). This therapeutic RNA is expressed from a retroviral vector
following ex vivo transduction and reinfusion of CD34+ HPCs. A
similar anti-HIV decoy is composed of the transactivating region
(TAR) hairpin at the 50 end of viral mRNA transcripts that recruits
and binds the viral Tat protein (DiGiusto et al., 2010). While theChemistry & Biolnatural TAR transcript is located in the nucleus at the site of viral
transcription, the TAR decoy is designed to translocate to the
nucleolus, where it binds and sequesters the Tat protein from
its natural target (Li et al., 2005). As described earlier, this therapy
also includes an shRNA and a ribozyme and is expressed from
a lentiviral vector (pHIV7-shI-TAR-CCR5RZ) in autologous
CD34+ HPCs.
Catalytic RNAs: Ribozymes
Ribozymes are catalytic RNAs that function as enzymes and do
not require proteins for catalysis. Most known natural ribozymes
are self-processing RNAs that catalyze RNA cleavage and liga-
tion reactions. However, the substrate recognition domain of
ribozymes can be artificially engineered to stimulate site-specific
cleavage in cis (the samenucleic acid strand) or trans (a noncova-
lently linked nucleic acid) (Scherer and Rossi, 2003). Moreover,
ribozymes are amenable to in vitro selection and directed evolu-
tion to generate improved properties and new functions for
therapeutic and diagnostic reagents. Ribozymes can be engi-
neered to be allosterically activated by effector molecules, which
has led to the development of artificial ‘‘riboswitches’’ as biosen-
sors and synthetic biological tools (Liang et al., 2011; Wieland
et al., 2010). There are numerous types of ribozymes in biology,
but the most common ribozyme therapeutics are derived from
either ‘‘hammerhead’’ or ‘‘hairpin/paperclip’’ motifs.
Like siRNA/shRNA therapeutics, ribozymes can either be
delivered to the target cells in RNA form or can be transcribed
from therapeutic genes (Table 3). Due to poor stability of fully-
RNA ribozymes, therapies that rely on direct delivery often
require chemically stabilized ribozymes, including the following
modifications: 50-PS backbone linkage, 20-O-Me, 20-deoxy-
20-C-allyl uridine, and terminal inverted 30-30 deoxyabasic
nucleotides. All of these modifications were incorporated for
Angiozyme (RPI.4610), the first synthetic ribozyme tested in
clinical trials (Kobayashi et al., 2005). Currently licensed by
Merck-Sirna, Angiozyme is a ribozyme that targets the mRNA
of the vascular endothelial growth factor receptor-1 (VEGFR-1)ogy 19, January 27, 2012 ª2012 Elsevier Ltd All rights reserved 67
Table 3. Ribozymes in Clinical Trials
Company Drug Delivery Route Target Modification(s) Disease Phase Status
Merck-Sirna Angiozyme SC VEGFR-1 50-PS, 20-O-Me,
20-deoxy-20-C-allyl
uridine, inveted 30-30 dT
renal
cancer
II Completed
Merck-Sirna Heptazyme SC HCV IRES 50-PS, 20-O-Me,
20-deoxy-20-C-allyl
uridine, inveted 30-30 dT
HCV II Terminated
UCSD MY-2 Ex vivo, autologous
CD4+ T cells
HIV U5
and pol
Expressed in MMLV
vector
HIV I Completed
Johnson & Johnson,
St. Vincent’s Hospital
RRz1 Ex vivo, syngeneic
CD4+ T cells
HIV Tat
and Vpr
Expressed in MMLV
vector
HIV I Completed
Janssen-Cilag
Pty Ltd, UCLA
OZ1 (RRz1) Ex vivo,
autologous HPCs
HIV Tat
and Vpr
Expressed in MMLV
vector
HIV II Ongoing
City of Hope,
Benitec
CCR5 ribozyme Ex vivo,
autologous HPCs
CCR5 Expressed in lentiviral
vector
HIV 0 Ongoing
Ribozyme,
City of Hope
L-TR/Tat-neo Ex vivo,
autologous HPCs
HIV Tat
and Rev
Expressed in MMLV
vector
HIV II Completed
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Reviewto block angiogenesis and tumor growth. A Phase I trial success-
fully demonstrated no pharmacokinetic interactions between
Angiozyme and chemotherapeutic agents carboplatin and pacli-
taxel for 12 patients with advanced solid tumors (Kobayashi
et al., 2005). Another Phase I study evaluated the maximum
tolerated dose, pharmacokinetic variables, pharmacodynamic
markers, clinical response, and safety of daily subcutaneous
(SC) injection of Angiozyme for 28 patients with refractory solid
tumors (Weng et al., 2005). A Phase II trial (NCT00021021) for
patients with metastatic renal cancer was completed in 2009,
though details of this trial have not been published. The same
company also developed Heptazyme, a synthetic ribozyme
against hepatitis C virus (HCV). However, despite encouraging
results in Phase I and II trials (Sandberg et al., 2001; Tong
et al., 2002), this drug was discontinued after the observation
of vision loss in one animal during simultaneous testing in
nonhuman primates (Berk, 2006).
Several ribozymes against HIV have been clinically tested
using a gene therapy-based approach in CD4+ T cells or
CD34+ hematopoietic stem cells (HSCs), which differentiate
into various hematopoietic lineages including CD4+ T cells
(Amado et al., 2004; Macpherson et al., 2005; Michienzi et al.,
2003; Wong-Staal et al., 1998). Since HIV-1 preferentially infects
CD4+ T cells, the therapeutically modified CD4+ cells would be
protected from producing functional HIV-1 virus. Each of these
trials used either autologous (patient’s own cells) or syngeneic
(cells from identical twin) cell therapy, in which the cells are
harvested from the patient or healthy twin, treated with the
ribozyme-embedded gene therapy, and reinfused back into the
patient. Retroviral or lentiviral gene vectors were utilized for
these trials, which facilitates integration of the therapeutic genes
into the host genome and long-term gene expression after
integration. While all of these trials have demonstrated the safety
and feasibility of gene-delivered ribozyme therapy, none has
proven a clear survival advantage for the protected cells versus
the empty vector (control) transduced cells. This might be due
to the poor engraftment of transduced cells, limited efficacy of
the therapeutic ribozyme, chromatin silencing of the integrated68 Chemistry & Biology 19, January 27, 2012 ª2012 Elsevier Ltd All rribozyme, suboptimal ribozyme kinetics, or other possible
factors (Burnett and Rossi, 2009).
As mentioned earlier in the siRNA/shRNA section, a Phase
0 clinical study at the City of Hope uses gene-modified autolo-
gous CD34+ HPCs to deliver three RNA-based for the treatment
of HIV-1 (DiGiusto et al., 2010). In addition to the shRNA and the
TAR decoy encoded in the lentiviral gene vector, this therapeutic
expresses a hammerhead ribozyme that cleaves the mRNA of
the chemokine receptor 5 (CCR5) protein (Li et al., 2005). The
CCR5 receptor is expressed on a subset of CD4+ T cells and
serves as a coreceptor for HIV-1 infection. However, CCR5 is
not essential for normal T cell function and offers an attractive
target for anti-HIV therapeutics since, unlike many viral targets,
it is not prone to mutational escape.
Design and Delivery
In the development of RNA-based therapeutics, in vitro and
animal studies have specifically and efficiently treated infectious
diseases, gene disorders, and cancers by using siRNA/shRNAs
to induce PTGS, ribozymes to cleave mRNA transcripts, and
aptamers to bind and block targeted proteins. However, these
therapies have encountered obstacles in clinical testing,
including the efficiency and specificity of delivery, the stability
of the RNA drug, the minimization of immune stimulation, and
the prolonged duration of the drug. These issues have raised
serious concerns for several RNA-based drugs and turmoil
within the RNAi industry. In particular, Bevasiranib and AGN-
745, two intravitreally injected naked siRNAs for the treatment
of AMD and DME, were terminated due to the lack of patient
improvement and TLR-mediated inflammation (Dejneka et al.,
2008; Kleinman et al., 2008). Other RNA-based drugs, including
the Bcr-Abl and TKM-ApoB siRNAs and several anti-HIV ribo-
zymes, have been discontinued due to insufficient in vivo drug
efficacy (Burnett and Rossi, 2009; Koldehoff et al., 2007; Tie-
mann and Rossi, 2009). Therefore, the future progress of RNA
therapeutics relies heavily on improvements in the design of
RNA drugs and delivery technologies that can improve drug effi-
cacy and minimize off-target effects.ights reserved
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typically preferred for lung, eye, and skin applications, may
generate a proinflammatory response due to activation of TLRs
(Cho et al., 2009; Kleinman et al., 2008) and suffer from poor
cellular uptake and nuclease sensitivity of naked siRNAs. In
some cases, these problems can be alleviated encapsulating
the nucleic acid with a synthetic carrier, or introducing chemical
modifications to ONs, including clinically promising LNA and
spiegelmer conversions, which are expected to improve the
specificity, stability, and immunoresistance of RNA-based
drugs.
A major benefit of synthetic RNA drug carriers is the ability to
engineer tissue specificity in local or systemic delivery applica-
tions, thereby preventing nonspecific delivery and degradation
of the drug during transport. Biodegradable polymers, such as
the LODER delivery system and the Calando cyclodextrin
carrier, can be engineered to release the RNA drug over a local-
ized tissue area for a controllable duration. Carriers designed
from liposomes tend to accumulate in the liver, which is the in-
tended target for the SNALP-encapsulated siRNAs ALN-TTR01
and ALN-VSP02.
Ex vivo delivery is ideal for bacterial or lentiviral vectors that
express shRNAs, ribozymes, and/or aptamer-like RNA decoys.
This delivery method is the most direct method of introducing
therapeutic genes, though it is limited to certain cell types and
patient cohorts. However, as observed with the cell-based
gene therapy strategies of anti-HIV ribozymes, the efficacy of
the therapy is dependent upon the success of the transplant.
As an alternative, synthetic carriers can be modified to specifi-
cally deliver the RNA drug to desired cells or tissues. In partic-
ular, ligand-decorated nanoparticles (Davis et al., 2010) and
aptamer-mediated siRNAs (Neff et al., 2011; Pastor et al.,
2010) may increase drug efficiency while avoiding the effects
of off-target toxicity.
In addition to improvements in drug delivery for RNA thera-
peutics, advances in drug design may also improve drug
efficacy and reduce off-target toxicity. An example mentioned
earlier, an asymmetric 25/27-R Dicer substrates that bias incor-
poration of the guide ssRNA stand into RISC, increases the drug
potency and mitigate the off-target effects from loading of the
passenger RNA strand (Kim et al., 2005). Additionally, dual-
targeting siRNAs are designed so that both strands will be
incorporated into RISC and separately target different mRNA
transcripts with complete complementarity (Tiemann et al.,
2010). In contrast to siRNAs, which tend to saturate the natural
RNAi machinery and become toxic at high concentrations,
ribozymes can be combined with each other or with another
siRNA therapy to provide a multipronged approach. Other
combinations of multiple RNA-based drugs, as with siRNA-
aptamer chimeras, riboswitches, and gene therapy vectors,
may offer the advantages of improving drug specificity, reducing
the required drug dosage, and preventing disease resistance.
Future Prospects
While RNA-based therapeutics must overcome barriers in
clinical testing for future success, results from previous trials
have revealed important lessons. In general, siRNAs will require
some chemical modifications to minimize nonspecific inflamma-
tion, whereas natural or synthetic carriers should be employedChemistry & Biolfor efficient and tissue-specific delivery. Many of these consider-
ations have contributed to encouraging clinical results for several
siRNA drugs including CALAA-01, TD101, ALN-VSP02, and
ALN-RSV01. While these examples hint at the potential of siRNA
therapeutics, they also affirm the need for tailored carriers that
specifically target the intended cells.
Like siRNAs, ribozymes and aptamers face similar challenges
of delivery and off-target toxicity. These RNA drugs are
amenable to chemical modification and, for some applications,
delivery via gene therapy. The chemically modified and highly
specific aptamer Macugen has gained FDA approval for the
treatment of AMD, signifying the most notable success in RNA-
based therapeutics to date. The REG1 dual-aptamer therapeutic
highlights the versatility of RNA therapeutics, as one aptamer
serves as a controlling mechanism for the therapeutic aptamer.
Collectively, these and other examples of RNA-based thera-
peutics have demonstrated early promise in the treatment of
cancers, viruses, and genetic disorders. However, advanced
delivery strategies are critical to fully harness the power of
RNAi and the flexibility of RNA-based therapeutics. Engineered
designs, such as aptamer-siRNA chimeras and transferrin-
decorated nanoparticles, will continue to dramatically improve
the precision of delivery for RNA drugs. Therefore, the future
prospects of RNA-based drugs will require biochemical refine-
ments to maximize drug potency while minimizing off target
toxicity and immunogenicity.
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